Beijing Sun-Novo Pharmaceutical Research (688621.SH): Clinical trial application for the investigational project BTP0427 has been approved.
Beijing Sun-Novo Pharmaceutical Research (688621.SH) announced that recently, the company and its wholly-owned subsidiary Jiangsu Novo Biotech New Drug Research and Development Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, and the clinical trial application for the company's investigational project BTP0427 has been approved. BTP0427 is intended for the treatment of chronic heart failure with reduced ejection fraction, suitable for symptomatic treatment of chronic heart failure patients with cardiac systolic dysfunction, and as an alternative therapy for patients who have already received combination treatment with the same dose of a -blocker and a sinoatrial node If current inhibitor and whose condition is controlled.
Beijing Sun-Novo Pharmaceutical Research (688621.SH) announced that recently, the company and its wholly-owned subsidiary Jiangsu Novo Biotech New Drug Research and Development Co., Ltd. received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, and the clinical trial application for the company's investigational project BTP0427 has been approved. BTP0427 is intended for the treatment of chronic heart failure with reduced ejection fraction, suitable for symptomatic treatment of chronic heart failure patients with cardiac systolic dysfunction, as a replacement therapy for patients who have already received combination treatment with the same dose of beta-blockers and sinoatrial node If current inhibitors and whose condition is controlled.
Related Articles
ZHONGCHANG INTL (00859): Cui Xianzhi Appointed as Company Secretary, Authorized Representative and Process Agent
.png)
SCIENTECH (02291) repurchased 51,000 shares for HKD 566,100 on September 16.
NANHUA FUTURES (02691) repurchased 308,500 shares on September 16 for approximately HK$2.0794 million.
ZHONGCHANG INTL (00859): Cui Xianzhi Appointed as Company Secretary, Authorized Representative and Process Agent
SCIENTECH (02291) repurchased 51,000 shares for HKD 566,100 on September 16.
NANHUA FUTURES (02691) repurchased 308,500 shares on September 16 for approximately HK$2.0794 million.
RECOMMEND
